Please provide your email address to receive an email when new articles are posted on . Patients with MS had lower corneal nerve fiber density, corneal nerve branch density and corneal nerve fiber ...

Multiple sclerosis is a disease mainly associated with the slowing down of information processing and a lack of motor coordination. It is an incurable disease that leads to degeneration of the central ...

About 1 million people are living with multiple sclerosis in the U.S., and about 10% of those have PPMS, making it the least common form of the disease.

Criteria used by neurologists to assess for multiple sclerosis (MS) in adults may fail to identify the illness in children with imaging suspicious for the disease, an oversight that could delay ...

The results from more than one-third of late-stage clinical trials that tested multiple sclerosis drugs were never published in peer-reviewed journals — and studies with negative or inconclusive ...

Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.

NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...

A Sanofi experimental drug for multiple sclerosis delayed disability progression in a late-stage trial, but failed to reduce episodes of new or worsening symptoms compared to an existing treatment in ...

Differences in the complexity of the EEG signal (yellow and red colors) in a specific brain area between the group with advanced multiple sclerosis and the control group, and multifractal spectra ...